XGN

Exagen Inc. Common Stock
Data: 2026-01-30
$3.68
Price
-7.34%
Change
$12.23
52W High
$2.6701
52W Low

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Quick Stats
Jan 30, 2026

46.5

AI Score

HOLD

2.58

Volume Ratio

Mar 10, 2026

Next Earnings

9

+ve Days (30d)

21

-ve Days (30d)

XGN Stock Summary

Last updated Jan 30, 2026

XGN is currently trading at $3.68, positioned below its 200-day moving average of $7.93, suggesting bearish momentum. The stock has a 52-week range of $2.6701 to $12.23.

Technical Analysis: The 50-day moving average stands at $6.25, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 16.079, suggesting the stock is oversold and potentially undervalued.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.241, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates XGN at 46.5/100 with a HOLD recommendation.

XGN (Exagen Inc. Common Stock) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 16.079
CMF (20) -0.241
ROC (10) -23.81
ADX (14) 37.617
Indicator Value
MACD (12,26,9) -0.748
AROONOSC (14) -100.0
WILLAMS %R (14) -94.976
MFI (14) 13.473
XGN Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

XGN Price vs Max Options Open Interest
XGN Max Change In Options Open Interest

XGN Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

XGN Daily Out of Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

XGN Daily In the Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

XGN Most Active Options by Volume(near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Exagen Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

XGN Moving Averages Analysis

XGN (Exagen Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 4.4
20 5.08
30 5.47
50 6.25
100 8.44
200 7.93

XGN Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 92.0 million
Earnings/Share ($) -0.93
Net Proft Margin (%) -0.2994
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.858
EPS Estimate Next Year ($) -0.396
WallStreet Target Price ($) 14.7143
Most Recent Quarter